Following Fresenius’ launch of a €200 million healthcare venture fund in July, we invited Thomas Thestrup, managing director ...

French biotech OSE Immunotherapeutics has reported higher one-year survival rates with two combinations of its cancer vaccine Tedopi compared with chemotherapy alone in a Phase 2 lung cancer trial.

Helping biopharmaceutical innovators build scalable, manufacturable, and commercially viable processes from the start.

Each month, the European Medicines Agency’s human medicines committee (CHMP) weighs in on which drugs should reach European ...

Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule ...

Lakefront Biotherapeutics, formerly Galapagos, has sold five preclinical CAR-T assets to Belgian startup Armed Cell ...

French-Belgian biotech Osivax has reported disappointing Phase 2b results for its broad-spectrum influenza vaccine OVX836, ...

Paris-based Rivercell has raised $25 million (about €22 million) in seed funding to generate experimental data and build AI ...

Zealand Pharma will pay Generate Biomedicines $30 million (€27 million) upfront to discover protein drugs for obesity and ...

Zealand Pharma shares fell about 4% in Thursday trading after new Phase 2 results for its Roche-partnered obesity drug petrelintide showed encouraging weight loss but a modest improvement in blood ...

U.K. microbiome company Microbiotica has raised £36 million (€43 million), the first close of a Series C round led by the ...

Undecimal Bio has launched with $18 million (about €16 million) in seed funding to develop delivery molecules that carry gene ...